Sun Pharma’s GL0034 yields promising results in two Phase 1 trials
Sun Pharmaceutical Industries has unveiled positive results from two Phase 1 studies assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of GL0034, a novel long-acting GLP-1 receptor agonist, in non-obese and obese adults without diabetes. The findings will be presented in poster sessions at the American Diabetes Association’s 83rd Scientific Sessions in San Diego. One of […]